Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jan 1:4:93-101.
doi: 10.2174/1874082001004020093.

Adenosine dysfunction and adenosine kinase in epileptogenesis

Detlev Boison  1
Affiliations

Adenosine dysfunction and adenosine kinase in epileptogenesis

Detlev Boison. Open Neurosci J. .

Abstract

Traditionally, epilepsy has been considered to be a disorder of neuronal dysfunction. Based on this dogma, drug development efforts have largely focused on neurocentric model systems to screen for compounds that affect the function of neurons. Unfortunately, about 30% of all patients with epilepsy - or more than 20 million worldwide - are refractory to classical neurocentric pharmacotherapy. The failure of neurocentric pharmacotherapy in epilepsy requires radical rethinking and the search for novel therapeutic targets. Research from recent years suggests that epilepsy is a disorder of astrocyte dysfunction. Astrocytes are key regulators of the brain's own anticonvulsant adenosine. Thus, any dysfunction in astrocyte metabolism will drastically affect the brain's ability to control excitability via adenosinergic neuromodulation. This review will focus on the astrocyte-based enzyme adenosine kinase (ADK) as the key regulator of synaptic adenosine. Astrogliosis - a pathological hallmark of the epileptic brain - leads to overexpression of the adenosine-removing enzyme ADK and therefore to adenosine deficiency. Evidence from transgenic animals demonstrates that overexpression of ADK per se is sufficient to trigger seizures. Consequently, pharmacological inhibition of ADK is very effective in suppressing seizures that are refractory to classical antiepileptic drugs. The recent definition of ADK as rational target to predict and to prevent seizures in epilepsy has prompted the development of focal adenosine augmentation therapies (AATs) that have been designed to selectively reconstitute adenosinergic signalling within an area of astrogliosis-based adenosine-dysfunction. This therapeutic challenge has experimentally been met with polymeric or stem cell based brain implants to afford the focal delivery of adenosine.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Major routes of adenosine metabolism
See this image and copyright information in PMC

Similar articles

  • Therapeutic epilepsy research: from pharmacological rationale to focal adenosine augmentation.
    Boison D, Stewart KA. Boison D, et al. Biochem Pharmacol. 2009 Dec 15;78(12):1428-37. doi: 10.1016/j.bcp.2009.08.005. Epub 2009 Aug 12. Biochem Pharmacol. 2009. PMID: 19682439 Free PMC article. Review.
  • Adenosine dysfunction in epilepsy.
    Boison D. Boison D. Glia. 2012 Aug;60(8):1234-43. doi: 10.1002/glia.22285. Epub 2011 Dec 22. Glia. 2012. PMID: 22700220 Free PMC article. Review.
  • Adenosine dysfunction in astrogliosis: cause for seizure generation?
    Li T, Quan Lan J, Fredholm BB, Simon RP, Boison D. Li T, et al. Neuron Glia Biol. 2007 Nov;3(4):353-66. doi: 10.1017/S1740925X0800015X. Neuron Glia Biol. 2007. PMID: 18634566 Free PMC article.
  • Adenosine Augmentation Therapy.
    Boison D. Boison D. In: Noebels JL, Avoli M, Rogawski MA, Olsen RW, Delgado-Escueta AV, editors. Jasper's Basic Mechanisms of the Epilepsies [Internet]. 4th edition. Bethesda (MD): National Center for Biotechnology Information (US); 2012. In: Noebels JL, Avoli M, Rogawski MA, Olsen RW, Delgado-Escueta AV, editors. Jasper's Basic Mechanisms of the Epilepsies [Internet]. 4th edition. Bethesda (MD): National Center for Biotechnology Information (US); 2012. PMID: 22787649 Free Books & Documents. Review.
  • The adenosine kinase hypothesis of epileptogenesis.
    Boison D. Boison D. Prog Neurobiol. 2008 Mar;84(3):249-62. doi: 10.1016/j.pneurobio.2007.12.002. Epub 2007 Dec 23. Prog Neurobiol. 2008. PMID: 18249058 Free PMC article. Review.
See all similar articles

Cited by

See all "Cited by" articles

References

    1. White HS, Smith MD, Wilcox KS. Mechanisms of action of antiepileptic drugs. Int Rev Neurobiol. 2007;81:85–110. - PubMed
    1. Vajda FJE. Pharmacotherapy of epilepsy: New armamentarium, new issues. Journal of Clinical Neuroscience. 2007;14:813–823. - PubMed
    1. Rogawski MA, Bazil CW. New molecular targets for Antiepileptic drugs: alpha 2 delta, SV2A, and K(v)7/KCNQ/M potassium channels. Current Neurology and Neuroscience Reports. 2008;8:345–352. - PMC - PubMed
    1. Taylor CP, Angelotti T, Fauman E. Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta (alpha2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res. 2007;73:137–150. - PubMed
    1. Brill J, Klocke R, Paul D, Boison D, Gouder N, Klugbauer N, Hofmann F, Becker C-M, Becker K. Entla: A novel epileptic and ataxic Cacna2d2 mutant of the mouse. J Biol Chem. 2004;279:7322–7330. - PubMed

LinkOut - more resources